Adherence to CDC Recommendations for the Treatment of Uncomplicated Gonorrhea - STD Surveillance Network, United States, 2016

• Type of Material: Article
• Authors: Emily J. Weston, Emory University; Kimberly A Workowski, Emory University; Elizabeth Torrone, Emory University; Hillard Weinstock, Emory University; Mark R. Stenger, Emory University
• Language: English
• Date: 2018-04-27
• Publisher: Centers for Disease Control and Prevention
• Publication Version: Final Published Version
• Copyright Statement: © 2018, Department of Health and Human Services. All rights reserved.
• License: Creative Commons Creative Commons CC0 1.0 Universal
• Final Published Version (URL): http://dx.doi.org/10.15585/mmwr.mm6716a4
• Title of Journal or Parent Work: MMWR. Morbidity and mortality weekly report
• ISSN: 0149-2195
• Volume: 67
• Issue: 16
• Start Page: 473
• End Page: 476
• Keywords: Science & Technology; Life Sciences & Biomedicine; NEISSERIA-GONORRHOEAE; RESISTANCE; Public, Environmental & Occupational Health; TREATMENT-GUIDELINES
• Research Categories: Health Sciences, Immunology; Health Sciences, Public Health

Abstract

What is already known about this topic? CDC’s treatment recommendations for gonorrhea were revised in 2012 and 2015 based on emerging antimicrobial resistance. What is added by this report? In 2016, 81% of gonorrhea cases in seven jurisdictions were treated with the recommended regimen for uncomplicated gonorrhea (250 mg dose of ceftriaxone [IM] plus 1 g dose of azithromycin [PO]), but this varied by provider type. What are the implications for public health practice? Providers should be aware of the national guidelines for the treatment of sexually transmitted infections. Monitoring of treatment practices is a critical public health priority to help assure that patients receive the highest quality of care, and to address the emerging threat of antimicrobial-resistant gonorrhea.